Want to see HK:6872 full AI Analyst Report?
6872 Stock Chart & Stats
$112.10
-$3.20(-2.78%)
―
--
Day’s Range― - ―
52-Week Range$104.00 - $287.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)129.16K
Market Cap
HK$6.03B
Enterprise Value$10.69K
Total Cash (Recent Filing)HK$183.76M
Total Debt (Recent Filing)HK$28.65M
Price to Earnings (P/E)―
Beta-0.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding52,328,926
10 Day Avg. Volume200,745
30 Day Avg. Volume129,164
Financial Highlights & Ratios
PEG Ratio-12.90
Price to Book (P/B)63.75
Price to Sales (P/S)0.00
P/FCF Ratio-111.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest LeverageAt the latest reported date, debt was about 28.7M versus equity of 153.9M, a debt-to-equity ratio near 0.19. This relatively light leverage reduces fixed financial pressure and leaves more balance-sheet capacity to support operations while the company develops its pipeline.
Positive Equity PositionEquity turning positive in 2025 is an improvement from negative equity in 2023 and 2024. Although it does not remove the risk from continuing losses, the restored positive capital base offers greater financial resilience than the prior reported position over the next several quarters.
2024 Cash-Burn ImprovementOperating cash burn improved from about 98.1M in 2023 to 48.6M in 2024, showing that spending or working-capital demands can moderate. The benefit was not sustained in 2025, when burn rose to 87.2M, so this is only a limited supporting signal.
Bears Say
No Reported RevenueRevenue remained zero across 2023–2025, leaving no reported commercial traction or operating sales base. Without revenue, the company must fund development before demonstrating product demand, making future progress dependent on converting its biotech activities into a commercial business.
Persistent Net LossesLarge net losses persisted through 2025, with only a partial improvement in 2024 before worsening slightly again. Continued losses weaken retained capital and indicate that the business has not yet reached an earnings stage, increasing dependence on funding while development spending continues.
Negative Cash GenerationOperating and free cash flow were negative in each reported year, and cash burn increased again in 2025 after improving in 2024. This means losses are translating into substantial cash outflows, limiting internally funded growth and increasing the importance of available financing.
TenNor Therapeutics Suzhou Ltd. Class H News
6872 FAQ
What was TenNor Therapeutics Suzhou Ltd. Class H’s price range in the past 12 months?
TenNor Therapeutics Suzhou Ltd. Class H lowest stock price was $104.00 and its highest was $287.00 in the past 12 months.
What is TenNor Therapeutics Suzhou Ltd. Class H’s market cap?
TenNor Therapeutics Suzhou Ltd. Class H’s market cap is HK$6.03B.
When is TenNor Therapeutics Suzhou Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TenNor Therapeutics Suzhou Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is TenNor Therapeutics Suzhou Ltd. Class H overvalued?
According to Wall Street analysts TenNor Therapeutics Suzhou Ltd. Class H’s price is currently Undervalued.
Does TenNor Therapeutics Suzhou Ltd. Class H pay dividends?
TenNor Therapeutics Suzhou Ltd. Class H does not currently pay dividends.
What is TenNor Therapeutics Suzhou Ltd. Class H’s EPS estimate?
TenNor Therapeutics Suzhou Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TenNor Therapeutics Suzhou Ltd. Class H have?
TenNor Therapeutics Suzhou Ltd. Class H has 52,328,926 shares outstanding.
What happened to TenNor Therapeutics Suzhou Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TenNor Therapeutics Suzhou Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6872
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TenNor Therapeutics Suzhou Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
Company Description
TenNor Therapeutics Suzhou Ltd. Class H
TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Ascentage Pharma Group International
―
Mabwell (Shanghai) Bioscience Co., Ltd. Class H
―